Superior Quality IGF1-LR3 Peptides Powder For Bodybuilding CAS:143045-27-6

    Mechanism of Action

    The core effect of IGF‑1 LR3 comes from its ability to attach directly to IGF‑1 receptors on muscle, bone, and fat cells. Once bound, it activates two major signalling pathways – PI3K/Akt and MAPK – which drive protein synthesis, enhance glucose uptake into muscle tissue, and activate satellite cells (the muscle stem cells). Satellite cells normally lie dormant, but when stimulated they can fuse with existing muscle fibres, adding new myonuclei and increasing the fibre's capacity to grow. Additionally, the peptide has very low affinity for the six IGF‑binding proteins, so it remains free and bioactive in circulation far longer than standard IGF‑1, delivering a sustained anabolic stimulus that is remarkably consistent.

    A frequent source of confusion is the difference between IGF‑1 LR3, IGF‑1 DES, and Mechano Growth Factor (MGF). IGF‑1 DES is a truncated version lacking three amino acids, giving it a short half‑life of about twenty to thirty minutes and a primarily local effect. Users inject DES directly into a targeted muscle to get a brief, intense pump and site‑specific hyperplasia, but the effect does not linger. MGF, by contrast, is naturally produced in muscle after mechanical stress; it triggers the initial satellite‑cell activation but does not sustain protein synthesis over hours. IGF‑1 LR3 sits in the middle with its extended half‑life and systemic action, making it suitable for overall muscle growth, recovery, and metabolic enhancement without requiring the frequent, targeted injections that DES demands.

    ●Extended half‑life – twenty to thirty hours, compared to ten to twenty minutes for natural IGF‑1.

    ●Low binding to IGFBPs – more free, bioactive peptide remains in circulation.

    ●Systemic anabolic action – the peptide circulates to all muscles, not just the injection site.

    ●Practical 50‑mcg starting dose – easy to measure with insulin syringes and sensible for first‑time use.

    ●Resistance to proteolytic breakdown – the modified chain degrades much more slowly than native IGF‑1.

    ●No androgen receptor involvement – works through growth pathways independent of androgens.

    Lean Mass Accretion and Hyperplasia

    IGF‑1 LR3 strongly induces muscle hyperplasia – the creation of new muscle cells – rather than simply enlarging existing ones. This is significant because adult humans normally have a fixed number of muscle fibres; hyperplasia offers the possibility of actually increasing that number, contributing to a more permanent increase in muscularity. One practical approach is to inject the peptide immediately after a workout into the specific muscle group trained that day, although the systemic nature of LR3 means its effects spread throughout the body.

    Nutrient Partitioning and Body Composition

    The peptide improves how the body directs nutrients toward muscle tissue and away from fat storage. By increasing glucose uptake in muscle, it shuttles carbohydrates into the trained fibres rather than letting them be stored as adipose tissue. This effect also enhances the muscle fullness and the "pump" experienced during exercise. Many experienced users report a drier, harder look to their physique after several weeks of use, with noticeably improved vascularity and muscle density.

    Injury and Connective Tissue Repair

    Because IGF‑1 LR3 promotes collagen synthesis and connective‑tissue healing, it can accelerate recovery from minor injuries, tendonitis, or overuse problems in the knees, shoulders, or lower back. Users sometimes notice that chronic joint pains feel distinctly better during a cycle, and that they recover between workouts much more quickly than usual. This makes the peptide a useful addition during periods of high‑volume training or when returning from a layoff.

    Intra‑Cycle Enhancement and Preservation

    When used alongside anabolic steroids, IGF‑1 LR3 amplifies the muscle‑building effect by adding a separate growth pathway. Steroids primarily act on androgen receptors, while LR3 works through the IGF‑1 axis – the two mechanisms are additive. Moreover, the peptide is often employed toward the end of a steroid cycle to help protect the gains during the transition to post‑cycle therapy. Some reports also indicate that IGF‑1 LR3 can support testicular recovery during PCT by increasing the production of steroidogenic enzymes and LH receptors in the testes. However, care must be taken because selective oestrogen receptor modulators such as tamoxifen and nolvadex can lower natural IGF‑1 levels, creating a potential conflict during concurrent use.

    Reconstitution and Handling

    A standard 1‑mg vial of IGF‑1 LR3 is reconstituted with bacteriostatic water or sterile water. Many prefer bacteriostatic water because the benzyl alcohol helps preserve the peptide after the first puncture. The reconstituted product should be stored in a refrigerator. Because peptides can degrade when shaken vigorously, the vial should be swirled gently until the powder dissolves completely. Most users draw the required dose with a 0.5‑ml insulin syringe, which allows precise measurement in micrograms.

    Subcutaneous vs. Intramuscular Injection

    IGF‑1 LR3 can be injected either subcutaneously or intramuscularly. Subcutaneous injections into the abdomen or thigh fat are simple and produce reliable systemic absorption. Intramuscular administration directly into the muscle trained that day is also common, with some users believing it enhances local growth; however, the systemic nature of LR3 means any localised effect is modest. For general muscle growth, a daily subcutaneous dose is perfectly adequate.

    Starting Doses and Titration

    For a first cycle, a typical starting dose is 50 mcg per day. Some users begin as low as 20‑30 mcg to assess their response, especially to blood glucose changes. More experienced individuals may go up to 80‑100 mcg daily, but exceeding 100 mcg is not often recommended because the law of diminishing returns applies: higher doses do not produce proportionally greater muscle gains but do increase the risk of side effects. Women generally use much lower doses, often around 20 mcg per day.

    For illustration, a 50‑mcg dose drawn from a 1‑mg vial reconstituted with 2 ml of water requires 0.1 ml on the syringe.

    Pre‑workout or Post‑workout?

    The timing of the injection is a subject of debate. Some authorities argue that a pre‑workout injection, taken about ten minutes before training, aligns the peptide's peak concentration with the mechanical stimulus of exercise, thereby maximising muscle‑building signals. Others believe that a post‑workout injection, given immediately after training, works directly on already‑stimulated satellite cells and damaged fibres. In practice, both approaches have supporters, and the longer half‑life means that a single daily dose, taken whenever convenient, will maintain an elevated level of IGF‑1 for many hours. However, the pre‑workout approach does carry a higher risk of hypoglycaemia, so carbohydrate intake must be carefully managed.

    Standard 4‑6 Week Off‑Season Cycle

    A straightforward cycle for adding lean mass runs four to six weeks at 50‑80 mcg per day, injected once daily. Because of the daily injection schedule, local injection sites should be rotated. This relatively short duration reduces the chance of receptor desensitisation or long‑term metabolic disturbance.

    MGF‑IGF‑1 LR3 Alternating Protocol

    More complex cycles take advantage of the different time‑courses of MGF and IGF‑1 LR3. In one ten‑day protocol, MGF is injected post‑workout on odd days to trigger immediate satellite cell activation, and IGF‑1 LR3 is used on even days to drive sustained protein synthesis and systemic growth. This alternating pattern mimics the body's natural response to exercise, where an initial repair phase is followed by a prolonged anabolic phase. The cycle is short enough to avoid desensitisation and can be repeated after a two‑ to four‑week break.

    Long Off‑Periods Between Cycles

    The IGF‑1 receptor, like many peptide receptors, can become less responsive when stimulated continuously. For this reason, cycles are typically kept to four to six weeks, followed by a washout period of at least four weeks. Limiting the total number of cycles per year further preserves sensitivity.

    Stacking with Other Compounds

    IGF‑1 LR3 stacks effectively with low‑dose growth hormone, as the two work on parallel pathways. It is also used alongside insulin, though this combination requires extremely careful monitoring of blood glucose because both compounds increase glucose disposal dramatically.      Insulin‑sensitising drugs such as metformin might be considered to manage carbohydrate metabolism, but this should only be done under medical supervision.

    The reported half‑life of IGF‑1 LR3 generally ranges from twenty to thirty hours, meaning that a single injection maintains a considerable level of the peptide in the blood for more than a full day. Some sources, however, note a longer half‑life of fifty‑six to seventy‑two hours, which reflects differences in measurement methods and the peptide's stability in specific environments. What matters for the user is that a once‑daily injection yields a consistent anabolic background throughout the day and night, with the highest receptor binding occurring in the first twelve hours after administration.

    Diet and Nutrition While Using IGF‑1 LR3

    Proper nutrition is not merely supportive – it is mandatory. IGF‑1 LR3 increases glucose uptake into muscle, so dietary carbohydrate intake must be sufficient to prevent low blood sugar. A common recommendation is a minimum of 50 grams of simple carbohydrates before each injection, with fast‑acting sources such as white rice, bananas, or dates being popular choices. More conservative protocols call for 140‑150 grams of carbohydrates per day, spread across several meals. Protein intake should be high, at around 1.25 grams per pound of body weight from animal sources, because the peptide cannot build muscle from nothing – it merely partitions nutrients more efficiently.

    Hypoglycaemia

    Because IGF‑1 LR3 increases glucose disposal into muscle, the most immediate risk is low blood sugar. Symptoms can include dizziness, sweating, irritability, and confusion. This risk is directly correlated with dose and timing; pre‑workout injections without adequate carbohydrate intake are particularly dangerous. Keeping a source of quick sugar – orange juice, glucose tablets, or a sugary sports drink – on hand during the first few uses is a wise precaution.

    Tissue Growth and Proliferation

    As a growth factor, IGF‑1 LR3 can theoretically promote the expansion of any cell type bearing the appropriate receptor. Concern has been raised over potential intestinal or organ growth, especially at high doses or with very long cycles. However, the short cycles typical in bodybuilding practice are thought to minimise this risk. Nonetheless, the peptide should never be used by anyone with a personal or strong family history of cancer, because cancer cells often overexpress IGF‑1 receptors.

    Glucose Dysregulation

    With repeated cycles, some individuals may develop reduced insulin sensitivity or glucose intolerance. This is more likely when high doses are used frequently without sufficient periods off the peptide. Regular monitoring of fasting blood glucose can help detect early signs of metabolic disturbance.

    Joint Pain and Fluid Retention

    A small number of users report temporary joint discomfort, water retention, or headaches during the first week of a cycle. These effects usually resolve as the body adapts to the elevated growth signal.

    The approach to PCT after an IGF‑1 LR3 cycle depends on what other compounds were used. When the peptide is taken alone, no conventional PCT is necessary because IGF‑1 LR3 does not suppress the hypothalamic‑pituitary‑testicular axis. Nevertheless, a natural taper – reducing the dose over two weeks – can help the body resume its own IGF‑1 production.

    When IGF‑1 LR3 is used at the end of a steroid cycle, many experienced users include it as part of the PCT protocol. The peptide has been shown to increase steroidogenic enzymes and LH receptors in the testes, potentially aiding the restoration of natural testosterone production. A typical dose during PCT is 50‑80 mcg per day, often given as a single pre‑bed injection. Serms such as nolvadex or clomiphene are still necessary alongside the peptide; however, because nolvadex can lower natural IGF‑1 levels, some believe the two agents are best not taken at the same time. One strategy therefore is to complete the serm phase first, then introduce IGF‑1 LR3 for an additional two to four weeks to help solidify gains and accelerate full testicular recovery.

Trade names	Long R3-IGF-1; IGF-1 Long R3
CAS	143045-27-6
Molar mass	9117.60
Formula	C400H625N111O115S9
Purity	Above 98%
Apprarance	White crystalline powder

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                   

 

    IGF‑1 LR3 is a potent and unique peptide that operates through a mechanism entirely separate from androgens. Its extended half‑life makes it exceptionally convenient, requiring only a single daily injection, while its ability to induce hyperplasia and improve nutrient partitioning gives it advantages over many other muscle‑building compounds. However, it is not a magic bullet. Proper training and a high‑protein, carbohydrate‑sufficient diet remain essential for realising its benefits. Users should start with a modest 50‑mcg dose, inject once daily for four to six weeks, and monitor their blood glucose carefully, especially in the first week. A minimum four‑week break should follow each cycle. Those with a family history of cancer, diabetes, or heart disease should approach IGF‑1 LR3 with extreme caution – or not use it at all. When used responsibly, and as part of a well‑planned training and nutritional programme, IGF‑1 LR3 can be one of the most effective tools available for building high‑quality, dense muscle tissue that looks as impressive as it performs.

Hot Tags: superior quality igf1-lr3 peptides powder for bodybuilding cas:143045-27-6, China superior quality igf1-lr3 peptides powder for bodybuilding cas:143045-27-6 manufacturers, suppliers, factory